The Deal: Teva and Blackstone Life Sciences announced a $400 million strategic funding agreement spread across four years to support the continued clinical development of duvakitug, a human monoclonal antibody targeting TL1A.

The Terms: Blackstone will be eligible for regulatory and commercial milestones plus low single-digit royalties on worldwide sales. Duvakitug is currently in Phase 3 studies for ulcerative colitis and Crohn's disease, co-developed with Sanofi.

Signal: Asset-specific funding over general balance-sheet debt is the definitive "Pivot to Growth" model for high-risk Phase 3 programs in 2026.

The Deal: UCB secured worldwide exclusive rights to ATG-201, Antengene's CD19/CD3 bispecific T-cell engager for autoimmune diseases.

The Terms: Antengene receives $80 million upfront, with potential for over $1.1 billion in success-based milestones plus tiered royalties.

Signal: The massive deal size validates Antengene's steric hindrance masking technology, designed to reduce cytokine release syndrome (CRS) risk—a critical differentiator for TCEs moving into autoimmune indications.

The Milestone: J&J's nipocalimab received FDA Fast Track designation for systemic lupus erythematosus (SLE), marking the drug's fifth Fast Track across autoantibody-driven indications (joining HDFN, wAIHA, gMG, and Sjögren's).

The Data: Follows positive Phase 2b JASMINE results showing a reduction in lupus disease activity and steroid-sparing potential. J&J is actively enrolling the Phase 3 GARDENIA study.

Differentiator: Nipocalimab is currently the only FcRn blocker to demonstrate SLE disease activity reduction in a clinical trial.

Regulatory Hurdle: The FDA's complete response letter for the Hunter syndrome gene therapy cited concerns about phenotype classification, external control comparability, and whether CSF heparan sulfate levels adequately predict clinical benefit.

The Demand: The agency recommended a prospective, randomized, sham surgery-controlled study. Regenxbio plans to pursue a Type A meeting and potential resubmission with longer-term data.

Global First: China's NMPA granted global-first approval to rovadicitinib (Anxu), an oral JAK/ROCK dual inhibitor for first-line treatment of intermediate-2 or high-risk primary and secondary myelofibrosis.

Data: Announced positive one-year results from its Phase 2a study in Primary Biliary Cholangitis (PBC).

Impact: Data showed restoration of immune tolerance and a sustained, statistically significant separation of liver stiffness versus placebo twelve months after only two doses.

Superiority Data: Reported positive Phase 2 results in chronic spontaneous urticaria at the AAAAI Annual Meeting, demonstrating statistically superior efficacy versus Novartis's Xolair (omalizumab) in a head-to-head comparison.

Timeline: Phase 3 for CSU is expected to start H1 2026; BLA submission for seasonal allergic rhinitis planned by Q3 2026.

M&A: Entered a definitive agreement to acquire Corstasis Therapeutics, gaining Enbumyst (bumetanide nasal spray), the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure.

Terms: The deal includes $75 million upfront, up to $180 million in milestones, and worldwide royalties. Expected to close Q2 2026.

Merger Approval: Amicus stockholders formally approved the $4.8 billion BioMarin acquisition at a special meeting (74.79% represented, overwhelming majority in favor).

Impact: The transaction adds Galafold and Pombiliti + Opfolda to BioMarin's rare disease portfolio. Expected to close Q2 2026.

Leadership: Appointed Kenneth Sun as SVP and Head of Asia, based in Hong Kong.

Context: The appointment follows explosive growth in Asian out-licensing, which exceeded $130 billion in announced transaction value in 2025, up from approximately $14 billion in 2021.

Regulatory Shift: The FDA confirmed it "strongly recommends" a prospective, randomized, double-blind, sham surgery-controlled Phase 3 study before uniQure can submit a BLA for its Huntington's disease gene therapy.

Impact: This represents a significant reversal from prior FDA communications that had endorsed the Phase 1/2 program for accelerated approval. uniQure shares fell more than 35%.

Policy: CMS is accepting comments on its Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) request for information, seeking input on strengthening fraud prevention across Medicare and Medicaid.